Skip to main content

Aukera Therapeutics joins BaseLaunch Portfolio

We are excited to welcome Aukera Therapeutics as our newest portfolio company!

Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel, founded by Stefan Imseng and Dritan Liko. The company emerged from the laboratories of Michael Hall – who discovered TOR and made seminal contributions to unravel the biology of the mTOR pathway – and Timm Maier – who focuses on the structural biology of macromolecular complexes and particularly multienzymes and regulatory protein complexes. Deep biological insights on the mTOR pathway combined with state-of-the-art structural biology allowed the teams to unravel the structure-function relationships of mTOR complexes, opening up novel avenues to drug them.

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 for the treatment of rare diseases, cancer, and neurodegenerative diseases where Aukera’s approach uniquely addresses unmet medical needs.

Share this article

View all news

Sign up to receive our newsletter in your inbox.